News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeClinical Forum InsightsMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2025|
AES 2025|
NSGC 2025
Advertisement

Fredrik Piehl, MD

Advertisement

Articles by Fredrik Piehl, MD

Treating Multiple Sclerosis Throughout the Life Cycle of Disease

ByRobert Naismith, MD,Fredrik Piehl, MD,Riley Bove, MD,Ahmed Zayed Obeidat, MD, PhD
March 4th 2024
Advertisement

Latest Updated Articles

  • Treating Multiple Sclerosis Throughout the Life Cycle of Disease
    Treating Multiple Sclerosis Throughout the Life Cycle of Disease

    Published: March 4th 2024 | Updated:



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1

2

Patients Treated With REGENXBIO’s DMD Gene Therapy RGX-202 Exceed Expected Disease Trajectory on NSAA

3

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis

4

Exploring Depressive Symptoms in Low-IQ Youth with Refractory Epilepsy

5

Rituximab Displays Long-Term Effectiveness for Relapsing MS

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
HCP Live
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us